Dyslipidemic drugs in metabolic syndrome
Introduction: Metabolic syndrome predisposes to diabetes and atherosclerotic vascular disease. Statins reduce cardiovascular events, so all metabolic syndrome patients should be evaluated for dyslipidemia. Many patients fail to achieve lipid goals with statin monotherapy. Co-administration of ezetim...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2013-01-01
|
Series: | Indian Journal of Endocrinology and Metabolism |
Subjects: | |
Online Access: | http://www.ijem.in/article.asp?issn=2230-8210;year=2013;volume=17;issue=3;spage=472;epage=479;aulast=Siddiqi |
id |
doaj-69a4d3f494fd4407a6f828186c0e55c0 |
---|---|
record_format |
Article |
spelling |
doaj-69a4d3f494fd4407a6f828186c0e55c02020-11-24T22:43:59ZengWolters Kluwer Medknow PublicationsIndian Journal of Endocrinology and Metabolism2230-82102230-95002013-01-0117347247910.4103/2230-8210.111644Dyslipidemic drugs in metabolic syndromeSheelu S SiddiqiMisbahuddinFarida AhmadSyed Z RahmanAsad U KhanIntroduction: Metabolic syndrome predisposes to diabetes and atherosclerotic vascular disease. Statins reduce cardiovascular events, so all metabolic syndrome patients should be evaluated for dyslipidemia. Many patients fail to achieve lipid goals with statin monotherapy. Co-administration of ezetimibe (EZE) and atorvastatin (ATV) may enable more patients to achievelow-density lipoproteincholesterol (LDL-C) goal while avoiding risks of high-dose statin monotherapy. Materials and Methods: The present study compares rosuvastatin (Rsv) with a combination of (Atv) and (Eze). Metabolic syndrome patients, 30-70 years with LDL-C ≥130 mg/dl and a 10-year CHD risk score of 10% were randomized to double-blind treatment with (Rsv) 5 mg (n = 67) or (Atv) 10 mg+(Eze) 10 mg (n = 68) for 12 weeks. Results: LDL-C reduced significantly; (32.3% and 30.3%, P < 0.001) in (Atv)+(Eze) and (Rsv), respectively, but there was no significant difference between two arms. More patients achieved LDL-C goal of ≤100 mg/dl with (Atv)+(Eze) compared to (Rsv) (65% vs. 58%, P < 0.05). Triglycerides (TG) were reduced more with (Atv)+(Eze) compared to (Rsv) (28.1% and 21.4%, P < 0.001). Greater increase in high-density lipoprotein cholesterol (HDL-C) was observed with (Atv)+(Eze). Both treatments were well tolerated. Conclusion: This study shows that the combination of (Atv)+(Eze) has more efficacy and comparable safety to that of (Rsv).http://www.ijem.in/article.asp?issn=2230-8210;year=2013;volume=17;issue=3;spage=472;epage=479;aulast=Siddiqi3-hydroxy-3-methyglutaryl-CoAreductaseinsulin resistance syndromelow-density lipoproteincholesterolstatins |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Sheelu S Siddiqi Misbahuddin Farida Ahmad Syed Z Rahman Asad U Khan |
spellingShingle |
Sheelu S Siddiqi Misbahuddin Farida Ahmad Syed Z Rahman Asad U Khan Dyslipidemic drugs in metabolic syndrome Indian Journal of Endocrinology and Metabolism 3-hydroxy-3-methyglutaryl-CoA reductase insulin resistance syndrome low-density lipoproteincholesterol statins |
author_facet |
Sheelu S Siddiqi Misbahuddin Farida Ahmad Syed Z Rahman Asad U Khan |
author_sort |
Sheelu S Siddiqi |
title |
Dyslipidemic drugs in metabolic syndrome |
title_short |
Dyslipidemic drugs in metabolic syndrome |
title_full |
Dyslipidemic drugs in metabolic syndrome |
title_fullStr |
Dyslipidemic drugs in metabolic syndrome |
title_full_unstemmed |
Dyslipidemic drugs in metabolic syndrome |
title_sort |
dyslipidemic drugs in metabolic syndrome |
publisher |
Wolters Kluwer Medknow Publications |
series |
Indian Journal of Endocrinology and Metabolism |
issn |
2230-8210 2230-9500 |
publishDate |
2013-01-01 |
description |
Introduction: Metabolic syndrome predisposes to diabetes and atherosclerotic vascular disease. Statins reduce cardiovascular events, so all metabolic syndrome patients should be evaluated for dyslipidemia. Many patients fail to achieve lipid goals with statin monotherapy. Co-administration of ezetimibe (EZE) and atorvastatin (ATV) may enable more patients to achievelow-density lipoproteincholesterol (LDL-C) goal while avoiding risks of high-dose statin monotherapy. Materials and Methods: The present study compares rosuvastatin (Rsv) with a combination of (Atv) and (Eze). Metabolic syndrome patients, 30-70 years with LDL-C ≥130 mg/dl and a 10-year CHD risk score of 10% were randomized to double-blind treatment with (Rsv) 5 mg (n = 67) or (Atv) 10 mg+(Eze) 10 mg (n = 68) for 12 weeks. Results: LDL-C reduced significantly; (32.3% and 30.3%, P < 0.001) in (Atv)+(Eze) and (Rsv), respectively, but there was no significant difference between two arms. More patients achieved LDL-C goal of ≤100 mg/dl with (Atv)+(Eze) compared to (Rsv) (65% vs. 58%, P < 0.05). Triglycerides (TG) were reduced more with (Atv)+(Eze) compared to (Rsv) (28.1% and 21.4%, P < 0.001). Greater increase in high-density lipoprotein cholesterol (HDL-C) was observed with (Atv)+(Eze). Both treatments were well tolerated. Conclusion: This study shows that the combination of (Atv)+(Eze) has more efficacy and comparable safety to that of (Rsv). |
topic |
3-hydroxy-3-methyglutaryl-CoA reductase insulin resistance syndrome low-density lipoproteincholesterol statins |
url |
http://www.ijem.in/article.asp?issn=2230-8210;year=2013;volume=17;issue=3;spage=472;epage=479;aulast=Siddiqi |
work_keys_str_mv |
AT sheelussiddiqi dyslipidemicdrugsinmetabolicsyndrome AT misbahuddin dyslipidemicdrugsinmetabolicsyndrome AT faridaahmad dyslipidemicdrugsinmetabolicsyndrome AT syedzrahman dyslipidemicdrugsinmetabolicsyndrome AT asadukhan dyslipidemicdrugsinmetabolicsyndrome |
_version_ |
1725693490539528192 |